Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Παρόμοια τεκμήρια

• Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
  ανά: Bafadhel, M, κ.ά.
  Έκδοση: (2018)
• Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
  ανά: Bafadhel, M, κ.ά.
  Έκδοση: (2017)
• Investigating blood eosinophil count thresholds in patients with COPD
  ανά: Russell, R, κ.ά.
  Έκδοση: (2018)
• Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
  ανά: Pavord, I, κ.ά.
  Έκδοση: (2017)
• Case series of long-term macrolide therapy effect on eosinophil count in COPD
  ανά: Asciak, R, κ.ά.
  Έκδοση: (2017)